Welcure Drugs & Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
For the nine months, revenue was INR 0.349 million compared to INR 0.159 million a year ago. Net loss was INR 1.56 million compared to INR 0.087 million a year ago. Basic loss per share from continuing operations was INR 0.012 compared to INR 0.001 a year ago. Diluted loss per share from continuing operations was INR 0.012 compared to INR 0.001 a year ago.